Fig. 7: Theoretical and experimental efficacy of 177Lu-lilotomab alone or combined with G2/M arrest inhibitors in tumor samples from patients with NHL. | Leukemia

Fig. 7: Theoretical and experimental efficacy of 177Lu-lilotomab alone or combined with G2/M arrest inhibitors in tumor samples from patients with NHL.

From: The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest

Fig. 7

Theoretical (using the Bliss independence mathematical model) and experimental antiproliferative effects of 177Lu-lilotomab and/or MK-1775 or PD-166285 (18 h incubation). The analysis was done at day 1 and day 4 post treatment.

Back to article page